Navigation Links
Avastin Won't Extend Breast Cancer Survival: Study
Date:12/7/2012

By Kathleen Doheny
HealthDay Reporter

FRIDAY, Dec. 7 (HealthDay News) -- The drug Avastin (bevacizumab), when added to chemotherapy, does not improve disease-free survival in patients with triple-negative breast cancer any better than chemo alone, new research finds.

"Therefore, sadly for patients, we have nothing extra to add to chemotherapy for early, triple-negative breast cancer," Dr. David Cameron, a professor of oncology at Edinburgh University in Scotland, said in a news release from the American Association for Cancer Research.

He was scheduled to present the findings Friday at the 2012 San Antonio Breast Cancer Symposium.

Previous studies of Avastin had found benefit. However, in 2011, the U.S. Food and Drug Administration revoked approval of the drug for late-stage breast cancer, citing risks -- such as heart failure and severe high blood pressure -- that outweigh the benefits. The drug may still be used off-label, with doctors prescribing it to patients if they think that patient could be helped.

This new study signals the death of the drug for breast cancer, although it is helpful in other cancers, said Dr. Joanne Mortimer, director of Women's Cancer Programs for the City of Hope Comprehensive Cancer Center in Duarte, Calif. She reviewed the new findings.

Another physician took a different view, saying others should consider continuing research on the drug. "We have all seen some success stories with the drug, and Avastin may be a drug that works in only a select few," said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City.

Avastin is marketed by Genentech. Swiss drugmaker Hoffmann-La Roche, which acquired Genentech, sponsored the study.

For the new study, researchers randomly assigned nearly 2,600 patients with triple-negative operable primary invasive breast cancer to four or more cycles of chemotherapy. They used either an anthracycline-based or taxane-based chemo drug. One group also received a year of Avastin therapy.

Triple-negative breast cancer refers to those tumors that do not have estrogen or progesterone receptors or express the HER2/neu gene.

The researchers followed the women to see if the Avastin made a difference in disease-free survival. At a median follow-up of 32 months, no significant improvement occurred by adding Avastin.

Among those who received chemo alone, 107 died during the follow-up period, compared with 93 deaths in the group getting chemo plus Avastin, the investigators found.

Those in the Avastin group were more likely than the chemo-alone group to have problems such as severe high blood pressure and congestive heart failure.

The drug is effective in other cancers, Mortimer said. "It's a very important drug for lung, [gastrointestinal] and kidney cancers," she explained.

The drug is still listed in the recommendations for breast cancer treatment by the National Comprehensive Cancer Network. The not-for-profit is an alliance of 21 major international cancer centers, including City of Hope.

Health insurers turn to the recommendations when deciding which drugs to cover. Avastin is costly, about $112,000 a year for breast cancer patients.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

To learn more about breast cancer, visit the American Cancer Society.

SOURCES: Joanne Mortimer, M.D., director, Women's Cancer Program, City of Hope Comprehensive Cancer Center, Duarte, Calif.; Stephanie Bernik, M.D., chief, surgical oncology, Lenox Hill Hospital, New York City; Cancer Therapy & Research Center-American Association for Cancer Research, news release; Dec. 7, 2012, presentation, 2012 San Antonio Breast Cancer Symposium


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Interpreting the Avastin-Lucentis study for persons with macular degeneration
2. Avastin No Benefit to Older Lung Cancer Patients: Study
3. More Fake Avastin Found in U.S., FDA Says
4. No Benefit Seen in Extending Herceptin for Breast Cancer
5. Chemo May Extend Survival After Breast Cancers Return
6. NIH study finds leisure-time physical activity extends life expectancy as much as 4.5 years
7. Study: Repeated surgeries appear to extend life of patients with deadliest of brain cancers
8. Supportive Spouse May Extend Cancer Survival
9. Precautions for tick-borne disease extend beyond Lyme
10. New Drug Appears to Extend Survival in Advanced Prostate Cancer Patients
11. Golden age of prostate cancer treatment hailed as fourth drug in 2 years extends life
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin Won't Extend Breast Cancer Survival: Study
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In search of the ... with theme event of “K Warriors” on June 4, 2016 at Ashbury Hotel and ... event is sponsored and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda ...
(Date:5/27/2016)... ... , ... Two director-level employees of Horizon Blue Cross Blue Shield of New ... honorees. The award recognizes businesswomen who excel in their fields and who have ... MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign aimed ... human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also provides insight ... and industry leaders such as Bioness. , As patients feel increasingly concerned ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... to students studying complementary medicine. Allison Outerbridge is this year’s Life University ... on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... with discovery of thousands of defective respirators, according to court documents and SEC ... case of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
Breaking Medicine Technology: